Estrella Immunopharma, Inc. (ESLA): Total Liabilities
$13.54M
As of 2025-12-31
$9.26M
As of 2026-06-30
+72.2%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $13.54M | +351.9% | 2026-03-18, Balance as of period end |
| 2024-12-31 | $3.00M | n/a | 2026-03-18, Balance as of period end |
| 2024-06-30 | $180.7K | -98.2% | 2024-09-27, Balance as of period end |
| 2023-06-30 | $9.77M | n/a | 2024-09-27, Balance as of period end |
| 2022-12-31 | $2.65M | +63.4% | 2023-03-14, Balance as of period end |
| 2021-12-31 | $1.62M | n/a | 2023-03-14, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | 2025-12-31 | $13.54M | +351.9% |
| BioCardia, Inc. (BCDA) | 2025-12-31 | $2.52M | -12.8% |
| Cero Therapeutics Holdings, Inc. (CERO) | 2025-12-31 | $9.09M | +12.2% |
| Tevogen Inc. (TVGN) | 2025-12-31 | $12.62M | +24.5% |
| Eloxx Pharmaceuticals, Inc. (ELOX) | 2025-12-31 | $17.18M | -37.1% |
| AIM ImmunoTech Inc. (AIM) | 2025-12-31 | $15.56M | +56.7% |
| Exozymes Inc. (EXOZ) | 2025-12-31 | $2.57M | -1.5% |
| Zivo Bioscience, Inc. (ZIVO) | 2024-12-31 | $2.16M | -21.9% |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | $2.95M | -10.5% |
Compare ESLA, BCDA, CERO, TVGN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗